The anti-inflammatory cytokine IL-37 improves the NK cell-mediated anti-tumor response

References

• Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol. 2010;11:1014–9. doi: 10.1038/ni.1944.
   PubMed Web of Science ®Google Scholar
• Boersma B, Jiskoot W, Lowe P, Bourquin C. The interleukin-1 cytokine family members: role in cancer pathogenesis and potential therapeutic applications in cancer immunotherapy. Cytokine Growth Factor Rev. 2021;62:1–14. doi: 10.1016/j.cytogfr.2021.09.004.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Qin H, Ye K, Sun C, Qin Y, Li G, Wang H, Wang H. Dual role of IL-37 in the progression of tumors. Cytokine. 2022;150:155760. doi: 10.1016/j.cyto.2021.155760.
   PubMed Web of Science ®Google Scholar
• Su Z, Tao X. Current understanding of IL-37 in human health and disease. Front Immunol. 2021;12:696605. doi: 10.3389/fimmu.2021.696605.
   PubMed Web of Science ®Google Scholar
• Wang S, An W, Yao Y, Chen R, Zheng X, Yang W, Zhao Y, Hu X, Jiang E, Bie Y, et al. Interleukin 37 expression inhibits STAT3 to suppress the proliferation and invasion of human cervical cancer cells. J Cancer. 2015;6(10):962–969. doi: 10.7150/jca.12266.
   PubMed Web of Science ®Google Scholar
• Gao W, Kumar S, Lotze MT, Hanning C, Robbins PD, Gambotto A. Innate immunity mediated by the cytokine IL-1 homologue 4 (IL-1H4/IL-1F7) induces IL-12-dependent adaptive and profound antitumor immunity. J Immunol. 2003;170(1):107–113. doi: 10.4049/jimmunol.170.1.107.
   PubMed Web of Science ®Google Scholar
• Zhao JJ, Pan QZ, Pan K, Weng DS, Wang QJ, Li JJ, Lv L, Wang DD, Zheng HX, Jiang SS, et al. Interleukin-37 mediates the antitumor activity in hepatocellular carcinoma: role for CD57+ NK cells. Sci Rep. 2014;4(1):5177. doi: 10.1038/srep05177.
   PubMedGoogle Scholar
• Ge G, Wang A, Yang J, Chen Y, Yang J, Li Y, Xue Y. Interleukin-37 suppresses tumor growth through inhibition of angiogenesis in non-small cell lung cancer. J Exp Clin Cancer Res. 2016;35(1):13. doi: 10.1186/s13046-016-0293-3.
   PubMedGoogle Scholar
• Chen YH, Zhou BY, Wu XJ, Xu JF, Zhang JA, Chen YH, Liang SS. CCL22 and IL-37 inhibit the proliferation and epithelial-mesenchymal transition process of NSCLC A549 cells. Oncol Rep. 2016;36(4):2017–2024. doi: 10.3892/or.2016.4995.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Wang Y, Liang L, Gao Y, Chen J, Sun Y, Cheng Y, Xu Y. IL-37 mediates the antitumor activity in renal cell carcinoma. Med Oncol. 2015;32(11):250. doi: 10.1007/s12032-015-0695-7.
   PubMed Web of Science ®Google Scholar
• Wang WQ, Zhao D, Zhou YS, Hu XY, Sun ZN, Yu G, Wu WT, Chen S, Kuang JL, Xu GG, et al. Transfer of the IL-37b gene elicits anti-tumor responses in mice bearing 4T1 breast cancer. Acta Pharmacol Sin. 2015;36(4):528–534. doi: 10.1038/aps.2015.3.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhao JJ, Zhou ZQ, Pan QZ, Zhu Q, Tang Y, Xia JC, Weng DS. IL-37 induces anti-tumor immunity by indirectly promoting dendritic cell recruitment and activation in hepatocellular carcinoma. Cancer Manag Res. 2019;11:6691–6702. doi: 10.2147/CMAR.S200627.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhang J, He P, Han J, Sun C. Interleukin-37 suppresses hepatocellular carcinoma growth through inhibiting M2 polarization of tumor-associated macrophages. Mol Immunol. 2020;122:13–20. doi: 10.1016/j.molimm.2020.03.012.
   PubMed Web of Science ®Google Scholar
• Mei Y, Zhu Y, Teo HY, Liu Y, Song Y, Lim HY, Binte Hanafi Z, Angeli V, Liu H. The indirect antiangiogenic effect of IL-37 in the tumor microenvironment. J Leukoc Biol. 2020;107(5):783–796. doi: 10.1002/JLB.3MA0220-207RR.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhao M, Guo C, Chu H, Li W, Chen X, Wang X, Li Y, Jia Y, Koussatidjoa S, et al. Intracellular mature IL-37 suppresses tumor metastasis via inhibiting Rac1 activation. Oncogene. 2018;37(8):1095–1106. doi: 10.1038/onc.2017.405.
   PubMed Web of Science ®Google Scholar
• Sarhan D, Hippen KL, Lemire A, Hying S, Luo X, Lenvik T, Curtsinger J, Davis Z, Zhang B, Cooley S, et al. Adaptive NK cells resist regulatory T-cell suppression driven by IL37. Cancer Immunol Res. 2018;6(7):766–775. doi: 10.1158/2326-6066.CIR-17-0498.
   PubMed Web of Science ®Google Scholar
• Mariotti FR, Supino D, Landolina N, Garlanda C, Mantovani A, Moretta L, Maggi E. IL-1R8: a molecular brake of anti-tumor and anti-viral activity of NK cells and ILC. Semin Immunol. 2023;66:101712. doi: 10.1016/j.smim.2023.101712.
   PubMed Web of Science ®Google Scholar
• Nold-Petry CA, Lo CY, Rudloff I, Elgass KD, Li S, Gantier MP, Lotz-Havla AS, Gersting SW, Cho SX, Lao JC, et al. IL-37 requires the receptors IL-18Ralpha and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction. Nat Immunol. 2015;16(4):354–365. doi: 10.1038/ni.3103.
   PubMed Web of Science ®Google Scholar
• Allaire JM, Poon A, Crowley SM, Han X, Sharafian Z, Moore N, Stahl M, Bressler B, Lavoie PM, Jacobson K, et al. Interleukin-37 regulates innate immune signaling in human and mouse colonic organoids. Sci Rep. 2021;11(1):8206. doi: 10.1038/s41598-021-87592-2.
   PubMed Web of Science ®Google Scholar
• Landolina N, Mariotti FR, Ingegnere T, Alicata C, Ricci B, Pelosi A, Veneziani I, Azzarone BG, Garlanda C, Mantovani A, et al. IL-1R8 silencing improves the anti-tumor function of freshly isolated human NK cells. J Immunother Cancer. 2022;10(3):e003858. doi: 10.1136/jitc-2021-003858.
   PubMed Web of Science ®Google Scholar
• Mariotti FR, Petrini S, Ingegnere T, Tumino N, Besi F, Scordamaglia F, Munari E, Pesce S, Marcenaro E, Moretta A, et al. PD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression. Oncoimmunology. 2019;8(3):1557030. doi: 10.1080/2162402X.2018.1557030.
   PubMed Web of Science ®Google Scholar
• Bartha A, Gyorffy B. Tnmplot.com: a web tool for the comparison of gene expression in normal, tumor and metastatic tissues. Int J Mol Sci. 2021;22(5):2622. doi: 10.3390/ijms22052622.
   PubMed Web of Science ®Google Scholar
• Molgora M, Bonavita E, Ponzetta A, Riva F, Barbagallo M, Jaillon S, Popovic B, Bernardini G, Magrini E, Gianni F, et al. IL-1R8 is a checkpoint in NK cells regulating anti-tumour and anti-viral activity. Nature. 2017;551(7678):110–114. doi: 10.1038/nature24293.
   PubMed Web of Science ®Google Scholar
• Li L, Wei J, Suber TL, Ye Q, Miao J, Li S, Taleb SJ, Tran KC, Tamaskar AS, Zhao J, et al. IL-37-induced activation of glycogen synthase kinase 3beta promotes IL-1R8/Sigirr phosphorylation, internalization, and degradation in lung epithelial cells. J Cell Physiol. 2021;236(8):5676–5685. doi: 10.1002/jcp.30253.
   PubMed Web of Science ®Google Scholar
• Alves M, Borges DP, Kimberly A, Martins Neto F, Oliveira AC, de Sousa JC, Nogueira CD, Carneiro BA, Tavora F. Glycogen synthase kinase-3 beta expression correlates with worse overall survival in non-small cell lung cancer-A Clinicopathological series. Front Oncol. 2021;11:621050. doi: 10.3389/fonc.2021.621050.
   PubMed Web of Science ®Google Scholar
• Cabrera E, Raninga P, Khanna KK, Freire R. GSK3-β stimulates claspin degradation via β-TrCP ubiquitin ligase and alters cancer cell survival. Cancers Basel. 2019;11(8):1073. doi: 10.3390/cancers11081073.
   PubMed Web of Science ®Google Scholar
• Robertson H, Hayes JD, Sutherland C. A partnership with the proteasome; the destructive nature of GSK3. Biochem Pharmacol. 2018;147:77–92. doi: 10.1016/j.bcp.2017.10.016.
   PubMed Web of Science ®Google Scholar
• Yan X, Zhao J, Zhang R. Interleukin-37 mediates the antitumor activity in colon cancer through beta-catenin suppression. Oncotarget. 2017;8(30):49064–49075. doi: 10.18632/oncotarget.17093.
   PubMedGoogle Scholar